cancer
patient
higher
risk
like
sever
diseas
without
cancer
search
pubm
articl
publish
mar
articl
highlight
risk
cancer
patient
infect
identifi
report
limit
small
case
inadequ
clinic
prognost
inform
therefor
extend
studi
case
reveal
characterist
investig
prognosi
cancer
patient
warrant
studi
involv
patient
cancer
largest
kind
confirm
patient
cancer
higher
proport
sever
case
poorer
prognosi
patient
without
cancer
observ
tendenc
patient
followup
phase
better
prognosi
anticanc
treatment
phase
death
older
median
age
comorbid
survivor
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
outbreak
coronaviru
diseas
occur
china
rest
world
sinc
dec
link
sever
adult
respiratori
syndrom
coronaviru
accord
situat
report
world
health
organ
caus
confirm
case
death
global
mar
declar
public
health
emerg
intern
concern
rais
risk
assess
high
high
becom
global
pandem
consid
number
patient
infect
larg
still
increas
cancer
coexist
diseas
neglect
mani
patient
cancer
risk
infect
previou
studi
includ
cancer
patient
found
patient
cancer
higher
risk
deterior
rapidli
individu
without
cancer
case
patient
malign
among
total
patient
record
diagnos
februari
howev
still
could
fulli
understand
clinic
characterist
cancer
patient
abovement
studi
due
limit
sampl
size
conduct
multicentr
retrospect
studi
show
clinic
inform
outcom
cancer
patient
infect
case
four
design
hospit
multicentr
retrospect
observ
studi
identifi
cancer
patient
inpati
four
design
hospit
zhongnan
hospit
wuhan
univers
fifth
hospit
wuhan
seventh
hospit
wuhan
wuhan
hankou
hospit
patient
admit
hospit
jan
feb
studi
approv
ethic
commiss
zhongnan
hospit
wuhan
univers
waiver
inform
consent
due
public
health
outbreak
investig
diagnos
realtim
revers
transcript
polymeras
chain
reaction
assay
accord
recommend
protocol
small
number
case
describ
clinic
confirm
case
base
diagnosi
treatment
program
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
new
coronaviru
pneumonia
feb
nation
health
health
commiss
china
also
categor
patient
accord
diseas
sever
mild
case
defin
confirm
case
common
symptom
mild
radiograph
evid
pneumonia
sever
case
dyspnea
respiratori
failur
cancer
patient
divid
followup
group
ongo
treatment
group
followup
group
defin
routin
radic
treatment
finish
one
month
ongo
treatment
group
defin
anticanc
therapi
requir
finish
finish
one
month
detail
inform
medic
record
includ
epidemiolog
demograph
exposur
histori
smoke
histori
chronic
medic
ill
sign
symptom
admiss
comorbid
chest
radiographi
ct
find
laboratori
find
treatment
measur
collect
studi
clinic
outcom
follow
mar
data
check
two
research
compar
characterist
sever
mild
case
survivor
nonsurvivor
continu
variabl
describ
use
mean
standard
deviat
sd
normal
distribut
median
rang
express
descript
data
count
categor
variabl
statist
analys
perform
use
ibm
spss
statist
version
window
twosid
p
valu
less
consid
statist
signific
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
among
cancer
diagnos
cancer
lung
cancer
common
cancer
type
fortyfour
patient
cancer
survivor
routin
followup
radic
treatment
twentythre
patient
receiv
anticanc
treatment
recent
tabl
two
patient
still
ongo
anticanc
treatment
infect
among
patient
case
receiv
chemotherapybas
comprehens
therapi
case
periop
period
case
receiv
support
treatment
case
receiv
radiotherapi
combin
target
therapi
endocrinotherapi
rest
patient
receiv
endocrinotherapi
immunotherapi
treatment
pneumonia
tumour
progress
recurr
observ
patient
patient
fever
cough
tabl
half
short
breath
clinic
symptom
includ
fatigu
sputum
product
dyspnea
diarrhea
nausea
vomit
myalgia
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
hemoptysi
sever
patient
nonsurvivor
higher
proport
dyspnea
admiss
mild
vs
sever
vs
survivor
vs
nonsurvivor
vs
p
baselin
symptom
similar
mild
sever
case
gener
accord
result
comput
tomographi
ct
scan
patient
sever
baselin
ct
manifest
tabl
show
baselin
blood
test
result
similar
gener
infect
patient
lymphocytopenia
main
laboratori
find
accompani
increas
creactiv
protein
procalcitonin
cancer
patient
especi
sever
case
addit
observ
decreas
platelet
increas
blood
urea
nitrogen
lactat
dehydrogenas
sever
patientsnonsurvivor
landscap
treatment
display
tabl
clearli
compar
clinic
characterist
lung
cancer
cancer
distribut
cancer
differ
treatment
phase
diseas
sever
age
group
diseas
phase
show
figur
number
patient
lung
cancer
treatment
twice
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
followup
figur
digest
system
cancer
patient
rank
highest
proport
sever
condit
figur
proport
lung
digest
system
cancer
age
higher
cancer
figur
followup
deadlin
cfr
patient
lung
cancer
higher
digest
system
cancer
cancer
figur
note
death
case
patient
lung
cancer
treatment
phase
multicentr
retrospect
studi
report
largest
cohort
cancer
patient
patient
develop
ard
incid
rate
ard
cancer
cohort
cfr
rate
cancer
patient
infect
higher
overal
popul
accord
situat
report
case
confirm
around
world
mar
cfr
rate
approxim
contrast
crude
cfr
cohort
find
provid
evid
cancer
patient
could
poorer
outcom
consist
previou
studi
studi
cfr
patient
receiv
ongo
anticanc
treatment
recent
higher
mere
followup
postcanc
treatment
routin
followup
phase
radic
treatment
furthermor
observ
tendenc
patient
followup
phase
may
better
prognosi
treatment
figur
result
provid
evid
demonstr
patient
receiv
ongo
anticanc
treatment
recent
poorer
prognosi
patient
followup
phase
may
result
immun
compromis
effect
led
anticanc
treatment
noteworthi
studi
show
lung
cancer
common
cancer
type
account
may
higher
suscept
infect
type
cancer
may
two
main
reason
lung
cancer
account
larg
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
proport
cancer
case
lung
cancer
patient
ongo
anticanc
treatment
may
high
risk
nosocomi
infect
low
immun
sarscov
viral
particl
meanwhil
death
lung
cancer
anticanc
treatment
phase
indic
patient
lung
cancer
anticanc
treatment
phase
might
poor
prognosi
proport
sever
case
among
differ
kind
cancer
type
rang
digest
system
cancer
patient
rank
highest
howev
still
unclear
whether
differ
sever
infect
among
type
cancer
data
need
verifi
find
report
previou
studi
male
older
patient
higher
risk
infect
valid
cancer
cohort
patient
cancer
cohort
older
overal
patient
previou
report
may
patient
accompani
cancer
addit
found
sever
patient
tend
older
patient
mild
ill
indic
older
patient
increas
risk
critic
ill
patient
chronic
ill
also
higher
risk
sever
accord
previou
studi
cohort
also
observ
higher
proport
sever
patient
comorbid
compar
patient
mild
diseas
particularli
patient
concurr
hypertens
sever
account
major
sever
patient
studi
recent
studi
suggest
angiotensinconvert
could
host
receptor
high
bind
affin
besid
express
tumour
tissu
could
higher
adjac
tissu
express
heterogen
across
differ
cancer
type
clinic
cours
cancer
patient
lymphocytopenia
observ
especi
sever
patientsnonsurvivor
might
result
target
damag
sarscov
viral
particl
find
consist
previou
studi
covid
indic
lymphocytopenia
reflect
sever
way
treatment
antivir
regimen
use
patient
studi
knowledg
specif
remedi
yet
therefor
support
treatment
adopt
mainstay
therapi
cohort
cancer
patient
receiv
oxygen
therapi
patient
receiv
mechan
ventil
hospitalacquir
transmiss
account
cancer
patient
data
consist
previou
report
hospit
patient
one
centr
zhongnan
hospit
wuhan
univers
inhospit
patient
infect
hospitalacquir
transmiss
indic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
hospitalacquir
transmiss
also
import
way
infect
cancer
patient
addit
cancer
patient
higher
risk
even
complet
anticanc
treatment
cancer
patient
studi
followup
phase
radic
anticanc
treatment
regular
anticanc
treatment
follow
cancer
patient
need
visit
hospit
frequent
increas
risk
exposur
infect
besid
cancer
patient
might
complic
due
old
age
weaken
immun
system
side
effect
undergo
treatment
therefor
recommend
system
screen
conduct
among
hospit
cancer
patient
studi
also
observ
ongo
anticanc
treatment
interrupt
patient
diagnosi
fortun
observ
tumour
progress
treatment
pneumonia
one
hand
appropri
delay
treatment
reduct
frequenc
visit
hospit
cancer
patient
feasibl
hand
medic
oncologist
recommend
provid
profession
consult
cancer
patient
ensur
essenti
anticanc
treatment
studi
sever
limit
first
retrospect
studi
case
four
hospit
although
largest
cancer
patient
cohort
result
may
repres
entir
cancer
patient
popul
interpret
caution
second
specif
clinic
inform
insuffici
whether
influenc
therapi
prognosi
cancer
patient
analys
studi
therefor
extend
followup
recommend
patient
futur
larger
cancer
patient
cohort
multicentr
need
explor
detail
inform
cancer
patient
studi
report
clinic
characterist
outcom
cancer
patient
patient
within
followup
phase
ongo
anticanc
treatment
phase
risk
studi
show
patient
cancer
seem
higher
proport
sever
case
poorer
prognosi
tendenc
poor
prognosi
obviou
patient
anticanc
treatment
phase
pay
intens
attent
cancer
patient
especi
common
risk
factor
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
contributor
hyz
lww
yyc
qw
yqi
yy
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
author
declar
conflict
interest
thank
patient
frontlin
healthcar
worker
involv
studi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
